{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:16:57Z","timestamp":1788419817932,"version":"build-2803163510"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010876","name":"Shanghai University of Traditional Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010876","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-small cell lung cancer (NSCLC) management remains constrained by acquired resistance to targeted therapies and refractoriness to immune checkpoint inhibitors (ICIs), the latter driven largely by the immunosuppressive tumor microenvironment (TME). Bispecific antibodies (bsAbs) represent a promising modality capable of circumventing these therapeutic hurdles through proximity-driven dual-targeting mechanisms that co-block bypass signaling pathways and reverse immunosuppression. This study systematically analyzes the clinical trial landscape and developmental trajectory of bsAbs in NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically queried the Trialtrove database for interventional clinical trials evaluating bsAbs in NSCLC with an actual or anticipated study start date on or before 8 February 2026. Following the application of predefined inclusion and exclusion criteria, 374 trials were identified. Data concerning trial phase, mechanistic targets, sponsor typology, and geographic distribution were extracted and analyzed using a mechanism-based classification framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The clinical pipeline has expanded rapidly, with 78.9% (295\/374) of included trials initiated since 2021, predominantly led by industry sponsors (82.9%). The landscape is characterized by a predominance of early-phase studies, with Phase I and I\/II trials comprising 62.6% (234\/374) of the cohort, compared with 9.9% (37\/374) advancing to late-stage pivotal validation. Dual-signaling inhibitors and checkpoint-TME bsAbs constitute the majority of late-stage investigations, whereas T-cell engagers (TCEs) form a rapidly expanding early-phase cohort. Geographically, the United States and China collectively participate in 94% of trials with available location data, but their strategic priorities diverge. The US pipeline emphasizes early-stage, high-risk mechanistic exploration (74% in Phase I or I\/II), whereas trials conducted in mainland China are concentrated in late-stage validation of established target combinations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The clinical development of bsAbs in NSCLC has shifted decisively toward rationally engineered constructs designed to address specific resistance mechanisms. The global landscape reflects complementary regional strategies that balance high-risk mechanistic innovation with accelerated clinical execution. The integration of these precision-engineered modalities into standard care has the potential to reshape the therapeutic paradigm for advanced NSCLC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1901850","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:45:34Z","timestamp":1788417934000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The clinical trial landscape of bispecific antibodies in non-small cell lung cancer: mechanistic trends and developmental strategies"],"prefix":"10.3389","volume":"17","author":[{"given":"Zunyuan","family":"Li","sequence":"first","affiliation":[{"name":"Baoshan Hospital, Shanghai University of Traditional Chinese Medicine (Shanghai Baoshan Hospital of Integrated Traditional Chinese and Western Medicine)","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Baoshan Hospital, Shanghai University of Traditional Chinese Medicine (Shanghai Baoshan Hospital of Integrated Traditional Chinese and Western Medicine)","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Shi","sequence":"additional","affiliation":[{"name":"Baoshan Hospital, Shanghai University of Traditional Chinese Medicine (Shanghai Baoshan Hospital of Integrated Traditional Chinese and Western Medicine)","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Guo","sequence":"additional","affiliation":[{"name":"Baoshan Hospital, Shanghai University of Traditional Chinese Medicine (Shanghai Baoshan Hospital of Integrated Traditional Chinese and Western Medicine)","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guirong","family":"Dong","sequence":"additional","affiliation":[{"name":"Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhidan","family":"Liu","sequence":"additional","affiliation":[{"name":"Baoshan Hospital, Shanghai University of Traditional Chinese Medicine (Shanghai Baoshan Hospital of Integrated Traditional Chinese and Western Medicine)","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA. Cancer J. Clin."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR -mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2515135518763280","article-title":"Bispecific antibodies in Cancer immunotherapy","volume":"6","author":"Dahl\u00e9n","year":"2018","journal-title":"Ther. Adv. Vaccines Immunother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e473148","DOI":"10.1200\/EDBK-25-473148","article-title":"Bispecific antibodies in hematologic and solid tumors: current landscape and therapeutic advances","volume":"45","author":"Guidi","year":"2025","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"B6","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"930846","DOI":"10.3389\/fonc.2022.930846","article-title":"Availability and affordability of oncology drugs in 2012-2021 in China and the United States","volume":"12","author":"Huang","year":"2022","journal-title":"Front. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","article-title":"LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation","volume":"57","author":"Joller","year":"2024","journal-title":"Immunity"},{"key":"B9","doi-asserted-by":"publisher","first-page":"103456","DOI":"10.1016\/j.drudis.2022.103456","article-title":"Small biotechs versus large pharma: who drives first-in-class innovation in oncology?","volume":"28","author":"Kennedy","year":"2023","journal-title":"Drug Discov. Today"},{"key":"B10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.1073\/pnas.1919764117","article-title":"Combining microenvironment normalization strategies to improve cancer immunotherapy","volume":"117","author":"Mpekris","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1158\/2159-8290.CD-21-1345","article-title":"Preclinical characterization and phase I trial results of a bispecific antibody targeting PD-L1 and 4-1BB (GEN1046) in patients with advanced refractory solid tumors","volume":"12","author":"Muik","year":"2022","journal-title":"Cancer Discov."},{"key":"B13","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR exon 20 insertion\u2013mutated non\u2013small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study","volume":"39","author":"Park","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.copbio.2019.11.020","article-title":"Bispecific antibodies in cancer immunotherapy","volume":"65","author":"Rader","year":"2020","journal-title":"Curr. Opin. Biotechnol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMp2109826","article-title":"The drug-dosing conundrum in oncology \u2014 when less is more","volume":"385","author":"Shah","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"Van De Donk","year":"2023","journal-title":"The Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12943-018-0777-1","article-title":"Management of acquired resistance to EGFR TKI\u2013targeted therapy in advanced non-small cell lung cancer","volume":"17","author":"Wu","year":"2018","journal-title":"Mol. Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(24)02722-3","article-title":"Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China","volume":"405","author":"Xiong","year":"2025","journal-title":"The Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","article-title":"Overall survival with amivantamab\u2013lazertinib in EGFR-mutated advanced NSCLC","volume":"393","author":"Yang","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"100151","DOI":"10.1016\/j.lanwpc.2021.100151","article-title":"The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020","volume":"11","author":"Zhong","year":"2021","journal-title":"Lancet Reg. Health - West. Pac."},{"key":"B24","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrclinonc.2017.10","article-title":"The changing landscape of clinical trial and approval processes in China","volume":"14","author":"Zhou","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"114203","DOI":"10.1016\/j.isci.2025.114203","article-title":"Advances in the clinical application of bispecific antibodies in cancer therapy","volume":"28","author":"Zhou","year":"2025","journal-title":"iScience"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1901850\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:45:36Z","timestamp":1788417936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1901850\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":26,"alternative-id":["10.3389\/fphar.2026.1901850"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1901850","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1901850"}}